Sehouli J, Grabowski JP. Surgery in recurrent ovarian cancer. Cancer. 2019;125(S24):4598–601.
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–96.
Article PubMed PubMed Central Google Scholar
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304.
Froyman W, Landolfo C, De Cock B, Wynants L, Sladkevicius P, Testa AC, et al. Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. Lancet Oncol. 2019;20(3):448–58.
Hiett AK, Sonek JD, Guy M, Reid TJ. Performance of IOTA simple rules, simple rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women. Ultrasound Obstet Gynecol. 2022;59(5):668–76.
Article CAS PubMed Google Scholar
Basha MAA, Metwally MI, Gamil SA, Khater HM, Aly SA, Sammak E. Comparison of O-RADS, GI-RADS, and IOTA simple rules regarding malignancy rate, validity, and reliability for diagnosis of adnexal masses. Eur Radiol. 2021;31(2):674–84.
Rosati A, Gueli Alletti S, Capozzi VA, Mirandola M, Vargiu V, Fedele C, et al. Role of ultrasound in the detection of recurrent ovarian cancer: a review of the literature. Gland Surg. 2020;9(4):1092–101.
Article PubMed PubMed Central Google Scholar
Meys EM, Kaijser J, Kruitwagen RF, Slangen BF, Van Calster B, Aertgeerts B, et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. Eur J Cancer. 2016;58:17–29.
Article CAS PubMed Google Scholar
Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the international ovarian tumor analysis (IOTA) group. Ultrasound Obstet Gynecol. 2000;16(5):500–5.
Article CAS PubMed Google Scholar
Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the international ovarian tumor analysis group. J Clin Oncol. 2005;23(34):8794–801.
Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C, et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol. 2008;31(6):681–90.
Article CAS PubMed Google Scholar
Van Calster B, Van Hoorde K, Valentin L, Testa AC, Fischerova D, Van Holsbeke C, et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ. 2014;349(2):g5920.
Article PubMed PubMed Central Google Scholar
Andreotti RF, Timmerman D, Strachowski LM, Froyman W, Benacerraf BR, Bennett GL, et al. O-RADS US risk stratification and management system: A consensus guideline from the ACR Ovarian-Adnexal reporting and data system committee. Radiology. 2020;294(1):168–85.
Guo Y, Zhao B, Zhou S, Wen L, Liu J, Fu Y, et al. A comparison of the diagnostic performance of the O-RADS, RMI4, IOTA LR2, and IOTA SR systems by senior and junior Doctors. Ultrasonography. 2022;41(3):511–8.
Article PubMed PubMed Central Google Scholar
Lee S, Lee JE, Hwang JA, Shin H, O-RADS US. A systematic review and Meta-Analysis of Category-specific malignancy rates. Radiology. 2023;308(2):e223269.
Zhang Q, Dai X, Li W. Systematic review and Meta-Analysis of O-RADS ultrasound and O-RADS MRI for risk assessment of ovarian and adnexal lesions. AJR Am J Roentgenol. 2023;221(1):21–33.
Strachowski LM, Jha P, Chawla TP, Davis KM, Dove CK, Glanc P, et al. O-RADS for ultrasound: A user’s guide, from the AJR special series on radiology reporting and data systems. AJR Am J Roentgenol. 2021;216(5):1150–65.
Strachowski LM, Jha P, Phillips CH, Blanchette Porter MM, Froyman W, Glanc P, et al. Radiology. 2023;308(3):e230685. O-RADS US v2022: An Update from the American College of Radiology’s Ovarian-Adnexal Reporting and Data System US Committee.
Andreotti RF, Timmerman D, Benacerraf BR, Bennett GL, Bourne T, Brown DL, et al. Ovarian-Adnexal reporting lexicon for ultrasound: A white paper of the ACR Ovarian-Adnexal reporting and data system committee. J Am Coll Radiol. 2018;15(10):1415–29.
Ma X, Zhao Y, Zhang B, Ling W, Zhuo H, Jia H, et al. Contrast-enhanced ultrasound for differential diagnosis of malignant and benign ovarian tumors: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2015;46(3):277–83.
Article CAS PubMed Google Scholar
Xie WT, Wang YQ, Xiang ZS, Du ZS, Huang SX, Chen YJ, et al. Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses. J Ovarian Res. 2022;15(1):15.
Article PubMed PubMed Central Google Scholar
Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;319(6):595–606.
Shin KH, Kim HH, Kwon BS, Suh DS, Joo JK, Kim KH. Clinical usefulness of Cancer antigen (CA) 125, human epididymis 4, and CA72-4 levels and risk of ovarian malignancy algorithm values for diagnosing ovarian tumors in Korean patients with and without endometriosis. Ann Lab Med. 2020;40(1):40–7.
Article CAS PubMed Google Scholar
Anastasi E, Farina A, Granato T, Colaiacovo F, Pucci B, Tartaglione S, et al. Recent insight about HE4 role in ovarian Cancer oncogenesis. Int J Mol Sci. 2023;24:13.
Qing X, Liu L, Mao XA, Clinical Diagnostic. Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis. Comput Math Methods Med. 2022:9339325.
Lycke M, Kristjansdottir B, Sundfeldt K. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018;151(1):159–65.
Ultrasound Branch of Chinese Medical Doctor Association. Chinese expert consensus on the clinical application of intravenous contrast enhanced ultrasound in obstetrics and gynecology(version2023). Chin J Ultrasonogr. 2023;32(7):553–65.
Yuan K, Huang YJ, Mao MY, Li T, Wang SJ, He DN, et al. Contrast-enhanced US to improve diagnostic performance of O-RADS US risk stratification system for malignancy. Radiology. 2023;308(2):e223003.
Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, et al. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet. 2016;293(4):695–700.
Cao L, Wei M, Liu Y, Fu J, Zhang H, Huang J, et al. Validation of American college of radiology Ovarian-Adnexal reporting and data system ultrasound (O-RADS US): analysis on 1054 adnexal masses. Gynecol Oncol. 2021;162(1):107–12.
Jha P, Gupta A, Baran TM, Maturen KE, Patel-Lippmann K, Zafar HM, et al. Diagnostic performance of the Ovarian-Adnexal reporting and data system (O-RADS) ultrasound risk score in women in the united States. JAMA Netw Open. 2022;5(6):e2216370.
Article PubMed PubMed Central Google Scholar
Hack K, Gandhi N, Bouchard-Fortier G, Chawla TP, Ferguson SE, Li S, et al. External validation of O-RADS US risk stratification and management system. Radiology. 2022;304(1):114–20.
Vara J, Manzour N, Chacón E, López-Picazo A, Linares M, Pascual MÁ, et al. Ovarian adnexal reporting data system (O-RADS) for classifying adnexal masses: A systematic review and Meta-Analysis. Cancers (Basel). 2022;14(13):3151.
Su N, Yang Y, Liu Z, Gao L, Dai Q, Li J, et al. Validation of the diagnostic efficacy of O-RADS in adnexal masses. Sci Rep. 2023;13(1):15667.
Article CAS PubMed PubMed Central Google Scholar
Liu Y, Cao L, Chen S, Zhou J. Diagnostic accuracy o
Comments (0)